Onkologie. 2022:16(1):6-9 | DOI: 10.36290/xon.2022.001

Imaging methods and their role in postoperative follow-up for renal carcinoma

Michal Standara
Oddělení radiologie, Masarykův onkologický ústav v Brně

Recommendations of professional authorities on follow-up imaging in patients after surgery for renal cancer vary. Despite general agreement on the need for individualization according to the degree of risk in a particular patient, risk stratification methods are not consistent. In the practice, the resultant follow-up pattern is always an intersection of the need to detect disease recurrence in an early stage, minimization of the patient's radiation burden, and availability of a particular imaging modality. Most recommendations suggest that, in the first three years after surgery, follow-up with CT of the chest and abdomen should be done at least once a year; in the following years, particularly in the low-risk group, the frequency of testing can be reduced.

Keywords: kidney cancer, recurrence, follow-up, imaging, CT.

Published: February 22, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Standara M. Imaging methods and their role in postoperative follow-up for renal carcinoma. Onkologie. 2022;16(1):6-9. doi: 10.36290/xon.2022.001.
Download citation

References

  1. Poprach A, Bortlîček Z, Büchler T, et al. Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database. Med Oncol. 2012;29(5):3314-3320. Go to original source... Go to PubMed...
  2. Dabestani S, Beisland C, Stewar, GD, Bensalah K, Gudmund­sson E, Lam TB, Gietzmann W, Zakikhani P, Marconi L, Fernandéz-Pello S, Monagas S, Williams SP, Torbrand C, Powles T, van Werkhoven E, Meijer R, Volpe A, Staehler M, Ljungberg B, Bex A. Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis. European Urology Focus 2019;5(5):857-866. https://doi.org/10.1016/j.euf.2018.02.010. Go to original source... Go to PubMed...
  3. Beisland Ch, Guðbrandsdottir G, Reisæter Lars AR, Bostad L, Hjelle KM. A prospective risk-stratified follow-up programme for radically treated renal cell carcinoma patients: evaluation after eight years of clinical use. World Journal of Urology 2016;34(8):1087-1099. https://doi.org/10.1007/s00345-016-1796-4. Go to original source... Go to PubMed...
  4. Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, de Kernion JB, Figlin RA, Belldegrun AS. Risk Group Assessment and Clinical Outcome Algorithm to Predict the Natural History of Patients With Surgically Resected Renal Cell Carcinoma. Journal of Clinical Oncology 2002;20(23). https://doi.org/10.1200/JCO.2002.05.111. Go to original source... Go to PubMed...
  5. Ramchandani P. Post-treatment surveillance of renal cancer renal cell. In: Patel U, et al. Carcinoma of the kidney, 1st ed. Cambridge: Cambridge University Press, 2008;185-202. Go to original source...
  6. Abu-Ghanem Y, Powles T, Capitanio U, Beisland Ch, Järvinen P, Stewart GD, Gudmundsson E, Lam BLT, Marconi L, Fernandéz-Pello S, Nisen H, Meijer RP, Volpe A, Ljungberg B, Klatte T, Bensalah K, Dabestani S, Bex A. Should patients with low-risk renal cell carcinoma be followed differently after nephron-sparing surgery vs radical nephrectomy? BJU Int. 2021;128(3):386-394. doi: 10.1111/bju.15415. Go to original source... Go to PubMed...
  7. van Poppel H, da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A, Colombel M, Klotz L, Skinner E, Keane T, Marreaud S, Collette S, Sylvester R. A Prospective, Randomised EORTC Intergroup Phase 3 Study Comparing the Oncologic Outcome of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma. A European Urology 2011;59(4). https://doi.org/10.1016/j.eururo.2010.12.013. Go to original source... Go to PubMed...
  8. Levy DA, Slaton JW, Swanson DA, Dinney CP. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. The Journal of Urology 1998; 159(4). Go to original source... Go to PubMed...
  9. Kim SP, Weight CJ, Leibovich BC, Thompson RH, Costello BA, Cheville JC, Lohse CM, Boorjian SA. Outcomes and Clinicopathologic Variables Associated With Late Recurrence After Nephrectomy for Localized Renal Cell Carcinoma.Urology 2011;78(5). https://doi.org/10.1016/j.urology.2011.05.012. Go to original source... Go to PubMed...
  10. Miyao N, Naito S, Ozono S, Shinohara N, Masumori N, Igarashi T, Nakao M, Tsushima T, Senga Y, Horie S, Kanayama H, Tokuda N, Kobayashi M. Late Recurrence of Renal Cell Carcinoma: Retrospective and Collaborative Study of the Japanese Society of Renal Cancer. Urology 2011;77(2). https://doi.org/10.1016/j.urology.2010.07.462. Go to original source... Go to PubMed...
  11. Lane BR, Gill IS. 5-Year Outcomes of Laparoscopic Partial Nephrectomy. Journal of Urology 2007;177(1). https://doi.org/10.1016/j.juro.2006.08.093. Go to original source... Go to PubMed...
  12. Russo P. Partial nephrectomy for renal cancer: Part I. BJU International 2010;105(9). https://doi.org/10.1111/j.1464-410X.2010.09339.x. Go to original source... Go to PubMed...
  13. Mayrhofer K, Niedersüß-Beke D. Evidence-based follow-up in renal cell carcinoma. Memo - Magazine of European Medical Oncology 2020;13(1):78-83. https://doi.org/10.1007/s12254-019-00540-9. Go to original source...
  14. Skolarikos A, Alivizatos G, Laguna P, de la Rosette J. A Review on Follow-Up Strategies for Renal Cell Carcinoma after Nephrectomy. European Urology 2007;51(6). https://doi.org/10.1016/j.eururo.2006.12.031. Go to original source... Go to PubMed...
  15. Hoffmann NE, Gillett MD, Cheville JC, Lohse CM, Leibovich BC, Blute ML. Differences in Organ System of Distant Metastasis by Renal Cell Carcinoma Subtype. Journal of Urology 2008;179(2). https://doi.org/10.1016/j.juro.2007.09.036. Go to original source... Go to PubMed...
  16. Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group strafitication system. Journal of Urology 2005;174(2). https://doi.org/10.1097/01.ju.0000165572.38887.da. Go to original source... Go to PubMed...
  17. Merrill SB, Sohl BS, Hamirani A, Lehman EB, Lehman KK, Kaag MG, Raman JD. Capturing Renal Cell Carcinoma Recurrences When Asymptomatic Improves Patient Survival. Clinical Genitourinary Cancer. 2019;17(2):132-138. https://doi.org/10.1016/j.clgc.2018.11.009. Go to original source... Go to PubMed...
  18. Herout R, Graff J, Borkowetz A, Zastrow S, Leike S, Koch R, Draeger DL, Protzel C, Hakenberg OW, Wirth MP, Froehner M. Surgical resection of locally recurrent renal cell carcinoma after nephrectomy: Oncological outcome and predictors of survival. Â Urologic Oncology: Seminars and Original Investigations 2018;36(1). https://doi.org/10.1016/j.urolonc.2017.08.021. Go to original source... Go to PubMed...
  19. Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, Weaver AL, Parker AS, Zincke H. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma. Cancer. 2003;97(7):1663-1671. https://doi.org/10.1002/CNCR.11234. Go to original source... Go to PubMed...
  20. Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P, Marconi L, Fernand-Pello S, Monagas S, Williams SP, Torbrand C, Powles T, van Werkhoven E, Meijer R, Volpe A, Staehler M, Ljungberg B, Bex A. Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival: Results from a European Multicentre Database (RECUR). European Urology 2019;75(2). https://doi.org/10.1016/j.eururo.2018.10.007. Go to original source... Go to PubMed...
  21. Stewart-Merrill SB, Thompson RH, Boorjian SA, Psutka SP, Lohse CM, Cheville JC, Leibovich BC, Frank I. Oncologic Surveillance After Surgical Resection for Renal Cell Carcinoma: A Novel Risk-Based Approach. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2015;33(35). https://doi.org/10.1200/JCO.2015.61.8009. Go to original source... Go to PubMed...
  22. Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Montes SFP, Giles RH, Hofmann F, Hora M, Kuczyk MA, Kuusk T, Lam TB, Marconi L, Merseburger AS, Powles T, Staehler M, Tahbaz R, Volpe A, Bex A. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. European Urology 2019;75(5):799-810. https://doi.org/10.1016/J.EURURO.2019.02.011. Go to original source... Go to PubMed...
  23. Motzer RJ, Jonasch E, Agarwal N. National Comprehensive CancerNetwork. Kidney Cancer. 2019;64.
  24. Donat SM, Diaz M, Bishoff JT, Coleman JA, Dahm P, Derweesh IH, Duke Herrell III S, Hilton S, Jonasch E, Wei Lin D, Edward Reuter V, Chang SS. Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline. The Journal of Urology 2013;190(2):407-416. https://doi.org/10.1016/J.JURO.2013.04.121. Go to original source... Go to PubMed...
  25. Stewart SB, Thompson RH, Psutka SP, Cheville JC, Lohse CM, Boorjian SA, Leibovich BC. Evaluation of the National Comprehensive Cancer Network and American Urological Association Renal Cell Carcinoma Surveillance Guidelines. Journal of Clinical Oncology 2014;32(36). https://doi.org/10.1200/JCO.2014.56.5416. Go to original source... Go to PubMed...
  26. Staudenherz A, Steiner B, Puig S, Kainberger F, Leitha T. Is there a diagnostic role for bone scanning of patients with a high pretest probability for metastatic renal cell carcinoma? Cancer. 1999;85(1). Go to original source...
  27. Henschke CI, McCauley DI, Yankelevitz DF, Naidich DP, McGuinness G, Miettinen OS, Libby DM, Pasmantier MW, Koizumi J, Altorki NK, Smith JP. Early Lung Cancer Action Project: overall design and findings from baseline screening. The Lancet. 1999;354(9173). https://doi.org/10.1016/S0140-6736(99)06093-6. Go to original source... Go to PubMed...
  28. Messerli M, Kluckert T, Knitel M, WÃlti S, Desbiolles L, Rengier F, Warschkow R, Bauer RW, Alkadhi H, Leschka S, Wildermuth S. Ultralow dose CT for pulmonary nodule detection with chest x-ray equivalent dose a prospective intra-individual comparative study. European Radiology 2017;27(8). https://doi.org/10.1007/s00330-017-4739-6. Go to original source... Go to PubMed...
  29. Wu N, Gamsu G, Czum J, Held B, Thakur R, Nicola G. Detection of small pulmonary nodules using direct digital radiography and picture archiving and communication systems. Journal of Thoracic Imaging 2006;21(1):27-31.https://doi.org/10.1097/01.RTI.0000203638.28511.9B Go to original source... Go to PubMed...
  30. Canvasser NE, Stouder K, Lay AH, Gahan JC, Lotan Y, Margulis V, Raj GV, Sagalowsky AI, Cadeddu JA. The Usefulness of Chest X-Rays for T1a Renal Cell Carcinoma Surveillance. Journal of Urology 2016;196(2). https://doi.org/10.1016/j.juro.2016.02.068. Go to original source... Go to PubMed...
  31. Meier-Schroers M, Homsi R, Skowasch D, Buermann J, Zipfel M, Schild HH, Thomas D. Lung cancer screening with MRI: results of the first screening round. Journal of Cancer Research and Clinical Oncology 2018;144(1). https://doi.org/10.1007/s00432-017-2521-4. Go to original source... Go to PubMed...
  32. Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P, Marconi L, Fernand-Pello S, Monagas S, Williams SP, Powles T, van Werkhoven E, Meijer R, Volpe A, Staehler M, Ljungberg B, Bex A. Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.). Scandinavian Journal of Urology 2019;53(1).https://doi.org/10.1080/21681805.2019.1588919. Go to original source... Go to PubMed...
  33. Mouracade P, Chavali JS, Kara O, Dagenais J, Maurice MJ, Nelson RJ, Rini BI, Kaouk JH. Imaging strategy and outcome following partial nephrectomy. Urologic Oncology: Seminars and Original Investigations 2017;35(11). https://doi.org/10.1016/j.urolonc.2017.06.052. Go to original source... Go to PubMed...
  34. Platzek I, Zastrow S, Deppe PE, Grimm MO, Wirth M, Laniado M, Stroszczynski C. Whole-body MRI in follow-up of patients with renal cell carcinoma. Acta Radiologica 2019;51(5). https://doi.org/10.3109/02841851003724846. Go to original source... Go to PubMed...
  35. Jain Y, Liew S, Taylor MB, Bonington SC. Is dual-phase abdominal CT necessary for the optimal detection of metastases from renal cell carcinoma? Clinical Radiology 2011;66(11). https://doi.org/10.1016/j.crad.2011.06.002. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.